Building the future of medicine in southern Sweden

Learn about Skåne: Sweden's cell & gene therapy powerhouse

Advanced Therapy Medicinal Products (ATMPs) — including gene therapies, somatic cell therapies, and tissue-engineered products — are reshaping the future of medicine. Sweden is emerging as a leader in this rapidly expanding sector, driven by world-class academic research, national infrastructure investments, and innovative local eco-systems like the one centred in Lund, Southern Sweden. This report highlights the status of Skåne’s ATMP landscape, the challenges and opportunities ahead, and how Lund’s unique model provides a scalable blueprint for national success.

The Rise of ATMPs: A New Era of Medicine

ATMPs hold transformative potential for treating diseases that were previously considered incurable. Sweden’s pharmaceutical exports now represent over 7% of total national exports, surpassing traditional industries. The national pharmaceutical market is expected to grow at 5-8% annually, while the cell and gene therapy sector is forecasted to surge by 25% annually.

Lund: Sweden’s Innovation Engine

Lund is home to 27 active ATMP projects as of 2024, supported by Lund University’s Stem Cell Center and the newly launched LU-ATMP Center. Research groups in Lund are leading efforts in Parkinson’s disease, oncology, neurology, and rare genetic conditions.